Oncotarget

Research Papers:

GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer

Jing Yang, Jing Wen, Tian Tian, Zhongsheng Lu, Yao Wang, Zikai Wang, Xiangdong Wang and Yunsheng Yang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:11788-11796. https://doi.org/10.18632/oncotarget.14352

Metrics: PDF 1836 views  |   HTML 2689 views  |   ?  


Abstract

Jing Yang1,*, Jing Wen2,*, Tian Tian3,*, Zhongsheng Lu1, Yao Wang4, Zikai Wang1, Xiangdong Wang1, Yunsheng Yang1

1Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China

2Department of Gastroenterology and Hepatology, Chinese PLA 261 Hospital, Beijing, China

3Nanlou Department of Respiratory Disease, Chinese PLA General Hospital, Beijing, China

4Department of Immunology/Bio-therapeutic, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, China

*These authors have contributed equally to this work

Correspondence to:

Yunsheng Yang, email: [email protected]

Keywords: meta-analysis, biomarker, colorectal cancer, survival, GLUT-1

Received: September 20, 2016     Accepted: December 20, 2016     Published: December 29, 2016

ABSTRACT

Background: Glucose transporter-1 (GLUT-1) exhibits altered expression in colorectal cancer (CRC). The aim of this study was to explore the association between GLUT-1 and survival conditions, as well as clinical features in CRC by meta-analysis.

Materials and Methods: Relevant studies were searched through predefined strategies, hazard ratios (HRs), odds ratios (ORs), and their 95% confidence intervals (CIs) were used as effective measures.

Results: A total of 14 studies with 2,077 patients were included in this meta-analysis. The results showed that GLUT-1 was not significantly associated with overall survival (OS) (HR=1.28, 95% CI=0.86–1.91, p=0.22) or disease-free survival (DFS) (HR=1.71, 95% CI=0.78–3.72, p=0.179). However, subgroup analysis indicated that GLUT-1 was a significant biomarker for poor DFS in rectal cancer (HR=2.47, 95% CI=1.21–5.05, p=0.013). GLUT-1 expression was also found to be significantly correlated with the presence of lymph node metastasis (n=8, OR=2.14, 95% CI=1.66–2.75, p<0.001), T stage (n=6, OR=1.73, 95% CI=1.17–2.58, p=0.007), higher Dukes stage (n=5, OR=2.92, 95% CI=2.16–3.95, p<0.001), female sex (n=4, OR=2.92, 95% CI=2.16–3.95, p<0.001), and presence of liver metastasis (n=3, OR=1.82, 95% CI=1.06–3.12, p=0.03).

Conclusion: In conclusion, this meta-analysis showed that GLUT-1 was associated with poor DFS in rectal cancer (RC). Furthermore, GLUT-1 was also an indicator of aggressive clinical features in CRC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14352